CS 1544-0975
Nonggongdanji-gil, Hongcheon-eup, Hongcheon-gun, Gangwon-do, Republic of Korea
TEL 033-435-4962
bgn4@bifido.com
ContactGet in touch helps us to
understand you better
Immune therapeutics
based on Bifidobacterium
Bifido Co., Ltd. was founded in 1999, in a spirit of challenge to pursue the best biotechnology and try to be the best in the field of human microbiome.
2019
09
NDI(New Dietary Ingredient) registered FDA
B.lactis AD011
2019
07
Bifido Shanghai office was established
2019
06
GRAS(Generally Recognized As Safe) registered FDA
B.longum BORI
2019
06
GRAS(Generally Recognized As Safe) registered FDA
B.bifidum BGN4
2018
12
be listed in KOSDAQ as 1st microbiome company
2018
09
NDI(New Dietary Ingredient) registered FDA
B.longum BORI
2018
08
NDI(New Dietary Ingredient) registered FDA
B.bifidum BGN4
2017
12
President’s commendation in export part.
2013
03
Second factory extension
2008
12
Awarded Excellent Researcher by Health Industry Technology Award
2007
12
Awarded Excellent Research Company by Health Industry Technology Award
2006
03
Designated as the GMP approved facility
2003
09
The first factory was established
2003
03
National Research Laboratory for probiotics was designated
1999
10
Bifido Co., Ltd. was established by prof. Ji
1988
Professor. Ji engaging in research of Bifidobacterium
OVER
National
SCI grade
Patents
Our team of microbiological experts is developing reliable technologies and products based on human-centered ideas.
We supply evidence based Bifidobacterium strains with various human clinical trials.
DETAILSPharmabiotics means human microbiome and its substances which can be used for medical purposes for the treatment of diseases.
DETAILSWe have selected novel Bifidobacterium strains which can improve the symptoms of RA in animal model and we expect a new pharmabiotics from those strains. We are now expanding our pipelines for other immune-related diseases, including cancer.
SEE PIPELINE